Recent studies provided first evidence that ARTD9 and DTX3L might act in a (poly or) mono-ADP-ribosylation-dependent DNA damage response pathway and together with ARTD1 enhance tumor cell survival [547, 548]. This evidence concerns the gene PARP9 and neoplasm.